Immunotherapy of Head and Neck Cancer: Current and Future Considerations

Rapidis, Alexander D.; Wolf, Gregory T.

doi:10.1155/2009/346345

Cited by 52 publications

(47 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In all cultures, both CD8þ and CD4þ T cells grew out (CD4/CD8 ratio median 2.45, average 5.1 and range 0. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19]. The composition of T cells was not clearly influenced by the culture conditions (Fig.…”

Section: Hpv-specific T Cells Can Be Isolated From Oropharyngeal Tumomentioning

confidence: 99%

“…13,14 In HNSCC a number of cytokine-, antibody-and vaccinebased immunotherapeutic approaches have been tested or are currently underway. [15][16][17] Recently, clinical success was achieved in the field of the immunotherapy of HPV16-induced (pre-) malignancies of the anogenital region, in particular with therapeutic vaccines. [18][19][20] Similar vaccine approaches are tested for the treatment of p53-overexpressing cancers.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Systemic and local human papillomavirus 16‐specific T‐cell immunity in patients with head and neck cancer

Heusinkveld

Goedemans

Briët

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

Squamous cell carcinomas of the head and neck (HNSCC), in particular those of the oropharynx, can be caused by human papilloma virus Type 16 (HPV16). Whereas these HPV-induced oropharyngeal carcinomas may express the HPV16 E6 and E7 oncoproteins and are associated with better survival, the nonvirally induced HNSCC are associated with overexpression of p53. In this study we assessed the presence of systemic and local T cells reactive against these oncoproteins in HNSCC. An exploratory study on the presence, type and function of HPV16-and/or p53-specific T cells in the blood, tumor and/or metastatic lymph node as measured by several immune assays was performed in an unselected group of 50 patients with HNSCC. Tumor tissue was tested for HPV DNA and the overexpression of p53 protein. Almost all HPV161 tumors were located in the oropharynx. Circulating HPV16-and p53-specific T cells were found in 17/47 and 7/45 tested patients. T cells were isolated from tumor cultures and/or lymph nodes of 20 patients. HPV16-specific T cells were detected in six of eight HPV1 tumors, but in none of the 12 HPV-tumors. Tumor-infiltrating p53-specific T cells were not detected. In depth analysis of the HPV16-specific T-cell response revealed that this response comprised a broad repertoire of CD41 T-helper Type 1 and 2 cells, CD41 regulatory T cells and CD81 T cells reactive to HPV16. The local presence of HPV16-specific T-cell immunity in HPV16-induced HNSCC implicates a role in the antitumor response and support the development of immunotherapy for HNSCC.

show abstract

Section: Hpv-specific T Cells Can Be Isolated From Oropharyngeal Tumomentioning

confidence: 99%

mentioning

confidence: 99%

Systemic and local human papillomavirus 16‐specific T‐cell immunity in patients with head and neck cancer

Heusinkveld

Goedemans

Briët

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Immunotherapy is becoming an attractive treatment in HNSCC (26). However, an adequate antigen candidate to immunotherapy is one whose expression is specific and stable, crucial to survival, and absent in normal cells (18).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of MAGE A1 in oral squamous cell carcinoma

et al. 2012

View full text Add to dashboard Cite

Abstract. MAGE A1 is a cancer testis antigen (CTA) described in a variety of human cancers. CTAs exhibit a highly restricted tissue expression and by virtue of their immunogenic potential, these genes are promising target molecules for cancer vaccines. DNA hypomethylation is associated with gene regulation in several types of tumours. The aim of this project was to identify the presence of MAGE A1 in oral squamous cell carcinoma (OSCC) samples and to investigate the hypomethylation profile of CpG islands situated in the promoter region of this gene. The expression of MAGE A1 in OSCC and healthy oral mucosal samples was determined by real-time quantitative and conventional endpoint PCR and also by immunohistochemistry staining. In addition, to investigate the hypomethylation profile of promoter MAGE A1 CpG islands, we performed bisulphite sequencing. Real-time quantitative and endpoint PCR assays demonstrated a lower level of MAGE A1 transcription. Endpoint PCR showed expression of MAGE A1 in 10% (2/20) of OSCCs. Sodium bisulphite sequencing analysis of MAGE A1 CpG islands did not reveal a difference between OSCC and normal oral mucosal samples. We further assessed MAGE A1 protein immunoexpression and found 80% (16/20) of immunopositivity in OSCCs. We did not observe a correlation between the presence of MAGE A1 protein and lower levels of transcripts. Identification of MAGE A1 protein in OSCCs and absence of immunoexpression in normal oral mucosa support the idea that this protein can be used as a biomarker for detection of OSCC; however, it is not associated with hypomethylation or high expression of the MAGE A1 gene.

show abstract

“…These rely on avoidance of detection (e.g. by down-regulating HLA expression), induced apoptosis of surrounding T-cells, and local suppressive immune modulation (98). In addition to direct antibodies against EGFR and VEGF mentioned above, immune modulators enhancing the host immune response such as interferon · and interleukin-2 could bear significant weight in treatment regimens.…”

Section: Escaping the Immune Responsementioning

confidence: 99%

Gene alterations in head and neck carcinomas and their role in promoting malignant behavior (Review)

Görögh¹

2010

Int J Oncol

View full text Add to dashboard Cite

Abstract. Head and neck squamous cell carcinoma (HNSCC) survival remains poor despite continuing efforts toward prevention, early detection, and improved treatment modalities. In part, this is thought to be due to a relative lack of molecular targeted therapeutic strategies beyond general mitosis inhibition, which sets a limit to what modern head and neck surgery can accomplish for advanced disease. The past 30 years have produced a large quantity of data, leading to a better understanding of HNSCC carcinogenesis and novel therapeutic agents, such as epidermal growth factor receptor blockers. This article reviews literature on the current understanding of molecular HNSCC carcinogenesis, and highlights the most promising therapeutic approaches.

show abstract

Immunotherapy of Head and Neck Cancer: Current and Future Considerations

Cited by 52 publications

References 67 publications

Systemic and local human papillomavirus 16‐specific T‐cell immunity in patients with head and neck cancer

Systemic and local human papillomavirus 16‐specific T‐cell immunity in patients with head and neck cancer

Evaluation of MAGE A1 in oral squamous cell carcinoma

Gene alterations in head and neck carcinomas and their role in promoting malignant behavior (Review)

Contact Info

Product

Resources

About